Skip to content

Effect of Huoxue Jiedu optimize recipe on carotid atherosclerosis with hyperlipidaemia :A Randomized Clinical Trial

Effect of Huoxue Jiedu optimize recipe on carotid atherosclerosis with hyperlipidaemia :A Randomized Clinical Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074283
Enrollment
Unknown
Registered
2023-08-03
Start date
2023-08-03
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid atherosclerosis with hyperlipidemia

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) 3 0 years old< age < 75 years old; (2) Meet the diagnostic criteria for primary hyperlipidemia and meet any of the following: TC=5.2mmol/L; LDL-C=3.4mmol/L; TG:1.7-5.2mmol/L; (3) Vascular ultrasound confirmed that it met the diagnostic criteria for carotid atherosclerosis, carotid intimal thickness (IMT) and carotid artery stenosis < 50%; (4) TCM differentiation is a mutual certificate of stasis; (5) Although taking lipid-lowering drugs, they have been discontinued for 2 weeks or more. (6) Voluntarily participate in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Previously diagnosed coronary heart disease, or uncontrolled hypertension (sitting diastolic blood pressure = 100 mmHg or systolic blood pressure =160 mmHg), or diabetes mellitus (glycosylated hemoglobin (HbA1c) =8.5%), or uncontrolled heart failure (NYHA grade = grade III) and arrhythmias with clinical symptoms or hemodynamic disorders; (2) Hyperlipidemia caused by drugs (phenothiazines, ß-blockers, adrenal corticosteroids and certain contraceptives, etc.), or patients who are using hormones, thyroxine therapy drugs and other drugs that affect blood lipid metabolism; (3) Combined with major diseases of liver, kidney and blood system, major infectious diseases, active rheumatic immune diseases, malignant tumors and psychosis; (4) Those who have had severe trauma or major surgery in the past six months, or have bleeding tendency; (5) Women who are currently or planning to be pregnant or lactating, or who are allergic to the test drug or the ingredients contained therein; (6) Those who participate in other clinical trials.

Design outcomes

Primary

MeasureTime frame
LDL-C;Carotid Intima-Media Thickness ;

Secondary

MeasureTime frame
TC;TG;HDL-C;plaque area;Integral of TCM Syndrome;

Countries

China

Contacts

Public ContactMei Xue/Lizhi LI

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

meiar@126.com+86 135 8190 2729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026